Please use this identifier to cite or link to this item:
Type: Conference item
Title: The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment
Author: Branford, S.
Yeung, D.
Ross, D.
Parker, W.
Braley, J.
Seymour, J.
Hughes, T.
Citation: Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 2014 / vol.124, iss.21, pp.816
Publisher: American Society of Hematology
Issue Date: 2014
ISSN: 0006-4971
Conference Name: 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
Statement of
Susan Branford, David T Yeung, David M Ross, Wendy T Parker, Jodi Braley, John F Seymour, and Timothy P. Hughes
Rights: © 2014 by The American Society of Hematology
RMID: 0030023652
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.